| abstract |
The present invention suppresses transient lower esophageal sphincter relaxation in combination with novel thiazole and oxazole derivatives having positive allosteric GABA B receptor (GBR) modulator activity, methods for producing the compounds, and optionally GABA B agonists And its use for treating gastroesophageal reflux disease and for treating functional gastrointestinal disorders and irritable bowel syndrome (IBS). This compound is represented by the general formula (I), wherein X 1 and X 2 are selected from O and N or S and N, and R 1 , R 2 and Y are as defined in the specification. . For example, R 1 can be alkyl, alkoxy, thioalkoxy or aryl, R 2 can be alkoxy, and Y can be a carbonylamino bond substituent including aryl or heteroaryl. |